Restore Mind Medicine

R&D Proposed Budget Line Item Internal Personnel Costs Commercial Consultant External R&D Collaborations (UHB) Digital Medicine MM-110 - Toxicology Studies MM-402 - Strategic Review and Phase I MM-120 - Phase III Proposal MM-120 - Phase III Start-up Costs MM-120 - Phase III Costs (50 patients) Preclinical and Other Programs Budget $3,600,000 Total $150,000 $4,000,000 $1,000,000 $75,000 $1,500,000 $20,000 $500,000 $12,500,000 $3,000,000 $26,345,000 ➜ 27% Savings MindMed's FY2022 R&D Cost: $36,169,000 These estimates are based on public data, industry trends, and experience. The Board will review and revise as needed should our slate be elected. 76

View entire presentation